Texas Biomedical Research Institute
Texas Biomed is dedicated to protecting human health through basic and translational research into infectious diseases. It aims to be the global leader in infectious disease research, working on breakthroughs that lead to diagnostics, vaccines, and therapies. The institute has a rich history of discoveries, including the first COVID-19 vaccine, Ebola treatment, and Hepatitis-C therapy, and operates high-level biocontainment labs and a National Primate Research Center. It focuses on research programs in Host-Pathogen Interactions, Disease Intervention & Prevention, and Population Health, with extensive resources including BSL-3 and BSL-4 labs, animal models, and advanced equipment. The institute also emphasizes education, workforce development, and global partnerships.
Industries
Nr. of Employees
large (251-1000)
Texas Biomedical Research Institute
San Antonio, Texas, United States, North America
Products
CoDe: codon deoptimization tool
Computational tool to recode RNA/DNA sequences via codon-pair deoptimization to attenuate viruses by increasing underrepresented codon pairs without altering amino acid sequences.
Meta-Transcriptome Detector (MTD) pipeline
Bash-executed pipeline for joint analysis of host transcriptome and microbiome using bulk and single-cell RNA-seq; generates count matrices, graphs and summary outputs.
Cell culture media and methods for generating alveolar macrophage–like cells
In vitro differentiation protocol using a surfactant and cytokine mixture to convert blood-derived monocytes into alveolar macrophage–like cells that retain phenotype and function for extended culture.
Involucrin-driven retroviral expression cassette vaccine platform
Vaccine platform using differentiation-specific transcriptional regulatory elements to direct antigen expression in epithelial stem cell lineages for mucosal antigen presentation.
Monoclonal antibodies and antigen-binding fragments for SARS-CoV-2
Human monoclonal antibodies and fragments with broad neutralizing activity described for therapeutic use against SARS-CoV-2 infections.
Compositions and methods for treating Schistosoma infections
Patent-disclosed composition(s) and methods intended to treat Schistosoma infections.
CoDe: codon deoptimization tool
Computational tool to recode RNA/DNA sequences via codon-pair deoptimization to attenuate viruses by increasing underrepresented codon pairs without altering amino acid sequences.
Meta-Transcriptome Detector (MTD) pipeline
Bash-executed pipeline for joint analysis of host transcriptome and microbiome using bulk and single-cell RNA-seq; generates count matrices, graphs and summary outputs.
Cell culture media and methods for generating alveolar macrophage–like cells
In vitro differentiation protocol using a surfactant and cytokine mixture to convert blood-derived monocytes into alveolar macrophage–like cells that retain phenotype and function for extended culture.
Involucrin-driven retroviral expression cassette vaccine platform
Vaccine platform using differentiation-specific transcriptional regulatory elements to direct antigen expression in epithelial stem cell lineages for mucosal antigen presentation.
Monoclonal antibodies and antigen-binding fragments for SARS-CoV-2
Human monoclonal antibodies and fragments with broad neutralizing activity described for therapeutic use against SARS-CoV-2 infections.
Compositions and methods for treating Schistosoma infections
Patent-disclosed composition(s) and methods intended to treat Schistosoma infections.
Services
Contract research and collaborative partnerships
On-site and collaborative preclinical research services including fee-for-service studies, contract research, experimental design consultation, grant support, research collaboration and licensing discussions.
Preclinical disease model services
Development and execution of rodent and nonhuman primate disease models across BSL-2/3/4 for testing diagnostics, therapeutics and vaccines, including telemetry and imaging endpoints.
Intellectual property licensing and technology commercialization
Assistance with licensing patent-protected technologies, collaborative development and commercialization of platform technologies and therapeutic candidates.
Contract research and collaborative partnerships
On-site and collaborative preclinical research services including fee-for-service studies, contract research, experimental design consultation, grant support, research collaboration and licensing discussions.
Preclinical disease model services
Development and execution of rodent and nonhuman primate disease models across BSL-2/3/4 for testing diagnostics, therapeutics and vaccines, including telemetry and imaging endpoints.
Intellectual property licensing and technology commercialization
Assistance with licensing patent-protected technologies, collaborative development and commercialization of platform technologies and therapeutic candidates.
Expertise Areas
- Infectious disease preclinical research
- Nonhuman primate model development and management
- Vaccine and therapeutic discovery and preclinical development
- Monoclonal antibody discovery and characterization
Key Technologies
- Biosafety level 4 (BSL-4) operations
- Biosafety level 3 (BSL-3) operations
- Nonhuman primate (NHP) models
- Telemetry for animal studies